论文部分内容阅读
美国研究者报道，ProteinDesignLabs公司的人抗巨细胞病毒抗体司韦单抗（seviru－mab，商品名Protovir）显然能改善天然巨细胞病毒（CMV）感染患者骨髓移植（BMT）的效果。在这一多中心11期临床研究中，179例这类病人接受多达7次的本品15或60mg或安慰剂。病人在BMT之前接受首次
Researchers in the United States reported that proteinDesignLabs’ human anti-cytomegalovirus antibody seviru-mab (trade name Protovir) apparently improves bone marrow transplantation (BMT) in patients with natural cytomegalovirus (CMV) infection. In this multicenter phase 11 clinical trial, 179 such patients receive up to 7 doses of this product, 15 or 60 mg, or placebo. The patient received the first visit before BMT